<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tatva Chintan Pharma Chem has filed its annual disclosure with BSE and NSE under SEBI's Large Corporate (LC) framework for FY 2024-25. The company confirmed that it does not qualify as a Large Corporate as per the applicability criteria in SEBI's August 2021 and October 2023 circulars. All fields in the Annexure XII-B2 format — including incremental borrowing, mandatory debt security borrowing, shortfall, and penalty — are marked as 'Not Applicable'. The filing was signed by Company Secretary Ishwar Nayi and CFO Ashok Bothra on 29 April 2025.
This is a routine SEBI compliance filing with no material impact on shareholders. It simply confirms the company falls below the Large Corporate borrowing threshold, meaning it has no obligation to raise a portion of its borrowings through listed debt securities.